Mitochondria in cancer
Authors:Debora Grasso1, Luca X. Zampieri1, Tânia Capelôa1, Justine A. Van de Velde1 and Pierre Sonveaux1
1 Pole of Pharmacology & Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
Keywords:
tumor metabolism, tricarboxylic acid (TCA) cycle, oxidative phosphorylation (OXPHOS), reactive oxygen species (ROS), apoptosis, mitophagy, mitochondrial biogenesis.
Abbreviatons:
2DG – 2-deoxy-D-glucose;
2HG – D-2-hydroxyglutarate;
3BP – 3-bromopyruvate;
α-KG – α-ketoglutarate;
α-TOS – α-tocopheryl succinate; ACO2 – aconitase 2;
AML – acute myeloid leukemia;
AMPK – AMP kinase;
Atg - autophagy-related;
Bcl-2 – B-cell lymphoma 2;
CoQ – coenzyme Q;
CS - citrate synthase;
CSC – cancer stem cell; DRP1 – dynamin-related protein 1;
EMT – epithelial to mesenchymal transition;
EOC – epithelial ovarian carcinoma;
ER – endoplasmic reticulum;
ETC – electron transport chain;
FAO – fatty acid oxidation;
FH – fumarate hydratase;
FoxO1 – forkhead O family protein 1;
FUNDC1 – FUN14 domain-containing 1;
GAPDH – glyceraldehyde-3-phosphate dehydrogenase;
GLUT – glucose transporter;
GSH – glutathione;
GST – glutathione S-transferase;
HIF – hypoxia-inducible factor;
HK – hexokinase;
Hsp70 – heat shock protein 70;
IDH – isocitrate dehydrogenase;
IMM – inner mitochondrial membrane;
IMS – intermembrane space;
KD – ketogenic diet;
KRAS – V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog;
LC3 – microtubule-associated protein light chain 3;
LDH-1 – lactate dehydrogenase-1;
MAVS – mitochondrial anti-viral signaling;
MCL-1 – myeloid leukemia cell differentiation protein-1;
Mdivi-1 – mitochondrial division inhibitor-1;
Mff – mitochondrial fission factor;
Mfn – mitofusin;
mtDNA – mitochondrial DNA;
mtROS - mitochondrial ROS;
mtSNP – single nucleotide polymorphism in mtDNA;
Nrf2 – nuclear factor erythroid-derived 2-like 2;
OMM – outer mitochondrial membrane;
Opa1 – optic atrophy protein 1;
OXPHOS – oxidative phosphorylation;
PDT – photodynamic therapy;
PEP – phosphoenolpyruvate;
PKA – cAMP-activated protein kinase A;
PINK1 – phosphatase and tensin homolog-induced kinase 1;
PTEN – phosphatase and tensin homolog;
ROS – reactive oxygen species;
SCO2 – synthesis of cytochrome oxidase 2;
SDH – succinate dehydrogenase;
Sirt – sirtuin;
SOD – superoxide dismutase;
TCA – tricarboxylic acid (cycle);
TERT – telomerase reverse transcriptase;
TGFβ – transforming growth factor β;
TIGAR – TP53-induced glycolysis and apoptosis regulator;
TNT – tunneling nanotube;
VDAC – voltage-dependent anion channel.
Corresponding Author(s):
Conflict of interest statement:
The authors declare no conflict of interest.
Please cite this article as:
Debora Grasso, Luca X Zampieri, Tânia Capelôa, Justine A. Van de Velde and Pierre Sonveaux (2020). Mitochondria in cancer. Cell Stress 4(6): 114-146. doi: 10.15698/cst2020.06.221
© 2020 Grasso et al. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduc-tion in any medium, provided the original author and source are acknowledged.
Abstract:
The rediscovery and reinterpretation of the Warburg effect in the year 2000 occulted for almost a decade the key functions exerted by mitochondria in cancer cells. Until recent times, the scientific community indeed focused on constitutive glycolysis as a hallmark of cancer cells, which it is not, largely ignoring the contribution of mitochondria to the malignancy of oxidative and glycolytic cancer cells, being Warburgian or merely adapted to hypoxia. In this review, we highlight that mitochondria are not only powerhouses in some cancer cells, but also dynamic regulators of life, death, proliferation, motion and stemness in other types of cancer cells. Similar to the cells that host them, mitochondria are capable to adapt to tumoral conditions, and probably to evolve to ‘oncogenic mitochondria’ capable of transferring malignant capacities to recipient cells. In the wider quest of metabolic modulators of cancer, treatments have already been identified targeting mitochondria in cancer cells, but the field is still in infancy.